Elgene Lim
Garvan Institute of Medical Research · 352 works · 16,289 citations · h-index 54
Top works
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
- ROAST: rotation gene set tests for complex microarray experiments
- A single-cell and spatially resolved atlas of human breast cancers
- Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways
- XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
- EMT, cell plasticity and metastasis
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
- CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
- 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
- Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
- Clinical Overview of MDM2/X-Targeted Therapies
- Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
- Targeting CDK2 in cancer: challenges and opportunities for therapy
- The natural history of hormone receptor-positive breast cancer.